Gland Pharma Settles Stock Exchange Fines Over Director Appointment Delay
Gland Pharma Ltd · Others (Uncategorized) · 13 Sept 2026, 8:57 pm
Gland Pharma Settles Stock Exchange Fines Over Director Appointment Delay Gland Pharma Limited addressed exchange-levied fines of ₹70,000 each from BSE and NSE regarding a 34-day technical breach of Regulation 17(1A) under SEBI LODR. The delay occurred while securing shareholder approval via postal ballot for appointing Non-Executive Independent Director Mr. William Keller, aged over 75, appointed on 15th Jun'26. Shareholders approved the special resolution on 18th Jul'26. The board reviewed the issue on 13th Sep'26, and the company has suo motu paid the full fine upfront to close the matter.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation · 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs · 16 Nov 2026
- Grant of Options to Purchase Securities · 16 Nov 2026
- Q2FY27 Earnings Call Transcript · 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company · 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 · 09 Nov 2026
- Q2FY27 Earnings Call Recording · 07 Nov 2026
- Q2Fy27 Investors presentation · 06 Nov 2026
